Frequency, type and severity of drug-related problems and pharmacist interventions in Paxlovid® prescribing: a descriptive analysis.

Background: Paxlovid® (nirmatrelvir and ritonavir) is the only licensed oral antiviral for COVID-19. Ritonavir is a potent inhibitor of cytochrome P450 enzymes causing numerous drug-drug interactions (DDIs).

Aim: To describe the frequency, type, and severity of detected drug related problems (DRPs) associated with Paxlovid®.

The behaviors and experiences of the community pharmacy team on the provision of multi-compartment compliance aids.

Background: Multi-compartment compliance aids (MCAs) are repackaging systems for solid dosage form medicines. Acknowledging the lack of evidence that MCAs improve adherence or clinical outcomes, the Royal Pharmaceutical Society has expressed concern that MCAs have 'become regarded as a panacea for medicines use'.

Objectives: To determine the behaviors and experiences of the community pharmacy team around MCA provision.

Promoting weight management services in community pharmacy: perspectives of the pharmacy team in Scotland.

Background: Obesity has reached pandemic levels with more than 1.4 billion adults affected worldwide. While there is a need to systematically develop and evaluate community pharmacy based models of weight management, it is imperative to describe and understand the perspectives of pharmacy staff.

Views of the Scottish general public on community pharmacy weight management services: international implications.

Background: Obesity has reached pandemic levels, with more than 1.5 billion adults being affected worldwide. In Scotland two-thirds of men and more than half of women are either overweight or obese, placing Scotland overall third behind the United States of America and Mexico.

Over-the-counter orlistat: early experiences, views and attitudes of community pharmacists in Great Britain.

Objectives Of The Study: To describe community pharmacists' early experiences, views and attitudes with over-the-counter orlistat, 9 months post legal re-classification from November 2009 to January 2010.

Setting: 13,200 (81%) randomly selected registered community pharmacies across Great Britain out of a potential 16,200.

Methods: A cross-sectional postal questionnaire survey of the main pharmacist with greatest responsibility for over-the-counter (OTC) supply.